公开(公告)号：US11560416B2

公开(公告)日：2023-01-24

申请号：US16606279

申请日：2018-04-20

Applicant: YUHAN CORPORATION

Inventor： Byung Hyun Choi ,  In Hwan Lim ,  Jun Young Park ,  Jin Hyoung Lee ,  Ki Hong Kim ,  Hae Yong Jo ,  Jun Hwan Kim ,  Moo Young Song ,  Jong Gyun Kim

IPC: C12N15/62 ,  C12N15/09 ,  C12N5/00 ,  C07K16/46 ,  C07K19/00 ,  C07K14/605 ,  C07K14/50 ,  C12P21/02 ,  C12N15/00

Abstract: A method for producing a dual function protein includes a biologically active protein and an FGF21 mutant protein. The method allows stable production of a target protein by effectively preventing decomposition of the target protein, and thus has a high potential for commercial usage.

公开(公告)号：US20210024638A1

公开(公告)日：2021-01-28

申请号：US16939472

申请日：2020-07-27

Applicant: ABL Bio Inc. ,  YUHAN CORPORATION

Inventor： Yeryoung Yong ,  Ui-Jung Jung ,  Hyejin Chung ,  Kyeongsu Park ,  Wonjun Son ,  Yangsoon Lee ,  Yeunju Kim ,  Eunsil Sung ,  Youngkwang Kim ,  Youngdon Pak ,  Minji Park ,  Jaehyun Eom ,  Hyoju Choi ,  Moo Young Song ,  Na Rae Lee ,  Young Bong Park ,  Eun-Jung Lee ,  Eun-Jung Lee

IPC: C07K16/28 ,  A61P35/00

Abstract: Provided are an anti-4-1BB/anti-EGFR bispecific antibody, and a pharmaceutical composition and a method for treating and/or preventing a cancer using the same.

公开(公告)号：US11479596B2

公开(公告)日：2022-10-25

申请号：US17256296

申请日：2019-07-24

Applicant: YUHAN CORPORATION ,  INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY

Inventor： Moo Young Song ,  Taejin Yoon ,  Jung-Sun Lee ,  Byung Hyun Choi ,  In Hwan Lim ,  Man Sil Park ,  Jin-Hyoung Lee ,  Hyoung Sig Seo ,  Hyeon Woo Kang ,  Sung Ho Kim ,  Eun Jig Lee ,  Jin Sook Yoon ,  Cheol Ryong Ku

IPC: A61K38/17 ,  A61K47/68 ,  C07K14/72 ,  C07K19/00 ,  A61K47/64 ,  A61K38/00

Abstract: Disclosed are a fusion protein comprising a thyrotropin receptor (TSHR) fragment and the use thereof. More specifically, disclosed are a fusion protein comprising a TSHR fragment comprising an extracellular domain of a wild-type TSHR and having a substitution of an amino acid at specific position and an immunoglobulin Fc region or a carboxy-terminal cap (C-CAP), and the use thereof. The fusion protein has improved pharmaceutical efficacy, in-vivo persistence and protein stability and a pharmaceutical composition containing the fusion protein as an active ingredient is useful as a therapeutic agent or diagnostic reagent for the alleviation of Graves' disease and Graves' ophthalmopathy.

公开(公告)号：US20210024650A1

公开(公告)日：2021-01-28

申请号：US16939536

申请日：2020-07-27

Applicant: ABL Bio Inc. ,  YUHAN CORPORATION

Inventor： Hyejin CHUNG ,  Yeryoung Yong ,  Kyeongsu Park ,  Eunyoung Park ,  Ui-Jung Jung ,  Yangsoon Lee ,  Eunjung Kim ,  Yong-Gyu Son ,  Wonjun Son ,  Seawon Ahn ,  Donghoon Yeom ,  Chanmoo Lee ,  Junghyeon Hong ,  Moo Young Song ,  Eun-Jung Lee ,  Na Rae Lee ,  Young Bong Park ,  Eun-Jung Lee ,  Taewang Kim

IPC: C07K16/32 ,  C07K16/28 ,  A61P35/00

Abstract: Provided are an anti-4-1BB/anti-HER2 bispecific antibody, and a pharmaceutical composition and a method for treating and/or preventing a cancer using the same.

公开(公告)号：US12168690B2

公开(公告)日：2024-12-17

申请号：US16939472

申请日：2020-07-27

Applicant: ABL Bio Inc. ,  YUHAN CORPORATION

Inventor： Yeryoung Yong ,  Ui-Jung Jung ,  Hyejin Chung ,  Kyeongsu Park ,  Wonjun Son ,  Yangsoon Lee ,  Yeunju Kim ,  Eunsil Sung ,  Youngkwang Kim ,  Youngdon Pak ,  Minji Park ,  Jaehyun Eom ,  Hyoju Choi ,  Moo Young Song ,  Na Rae Lee ,  Young Bong Park ,  Eun-Jung Lee ,  Eun-Jung Lee

IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395

Abstract: Provided are an anti-4-1BB/anti-EGFR bispecific antibody, and a pharmaceutical composition and a method for treating and/or preventing a cancer using the same.

公开(公告)号：US11505603B2

公开(公告)日：2022-11-22

申请号：US16970351

申请日：2019-02-28

Applicant: YUHAN CORPORATION

Inventor： Kwang-Hoon Lee ,  June Hyung Lee ,  Na Rae Lee ,  Eunjeong Jeong ,  Young Bong Park ,  Nakho Chang ,  Eun-Jung Lee ,  Ki Hong Kim ,  Sunghyun Choi ,  Byung Hyun Choi ,  Ju Young Park ,  Moo Young Song ,  Jong-Seo Lee ,  Kyu-Tae Kim ,  Bong-Kook Ko

IPC: A61K39/395 ,  C07K16/00 ,  C07K16/46 ,  C07H21/04 ,  C12N5/02 ,  C12N5/20 ,  C12N15/00 ,  C07K16/28 ,  A61K39/00

Abstract: Disclosed are a novel antibody specifically binding to the tumor-immunosuppressant, TIGIT (T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif [ITIM] domain) or an antigen-binding fragment thereof, a nucleic acid encoding the antibody or the antigen-binding fragment thereof, a vector and a host cell including the nucleic acid, a method for producing the antibody or the antigen-binding fragment thereof, a pharmaceutical composition containing the antibody or the antigen-binding fragment thereof as an active ingredient, and uses of the pharmaceutical composition.
The antibody specifically binding to TIGIT or the antigen-binding fragment thereof and the pharmaceutical composition containing the same as an active ingredient are preferably used for the treatment of cancer or tumors.

公开(公告)号：US11179440B2

公开(公告)日：2021-11-23

申请号：US16348249

申请日：2017-11-10

Applicant: YUHAN CORPORATION

Inventor： Han Na Hong ,  Jun Hwan Kim ,  Hyun Ho Choi ,  Dohoon Kim ,  Taewang Kim ,  Se Woong Oh ,  Moo Young Song ,  Jong Gyun Kim

IPC: A61K38/18 ,  A61P1/16 ,  A61K38/17 ,  A61K38/26

Abstract: A fusion protein containing a biologically active protein and an FGF21 mutant protein, a pharmaceutical composition containing the fusion protein, and their uses are disclosed. The fusion protein and the pharmaceutical composition are effective in treating a liver disease including hepatitis, hepatic fibrosis, and hepatic cirrhosis. The fusion protein has effects of inhibiting proliferation of inflammatory cells and fibroblasts, and thus can be effectively used for treating hepatitis, hepatic fibrosis, and hepatic cirrhosis.